This is a working overview of LC-MS/MS, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-03. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
The Culture is a fictional interstellar post-scarcity society created by the Scottish writer Iain M. Banks and features in a number of his space opera novels and works of short fiction, collectively called the Culture series. The Culture is composed primarily of humanoid aliens, artificial intelligences (A.I.), and a number of other sentient life forms. The A.I. intelligence covers a spectrum; simple programs performing a specific function (e.g. controlling spacesuits), human-equivalent drones and hyper-intelligent Minds who organise and oversee the society. Beyond scarcity, the Culture has no need for money; instead, Minds organise society to maximise the well-being of its citizenry. The protagonists, almost always humanoids, are generally those who have chosen to work for the Culture's diplomatic or espionage organs and interact with other civilisations whose citizens act under different ideologies, morals, and technologies. The Culture generally has more advanced technology relative to most other civilisations it shares the galaxy with. Most of the Culture's citizens do not live on planets but in artificial habitats such as orbitals and ships, the largest of which are home to billions of individuals. The Culture's citizens have been genetically enhanced to live for as long as they desire and have modified mental control over their physiology, including the ability to introduce a variety of psychoactive drugs into their systems, change biological sex, or switch off pain at will.
Earthworms use, in addition to the digestive proteins, a class of surface active compounds called drilodefensins, which help digest plant material by counteracting the inhibitory effects of polyphenols on earthworm gut enzymes. Instead of being coiled like a mammalian intestine, in the earthworm's intestine a large mid-dorsal, tongue-like fold is present, called a typhlosole, with many folds running along its length, increasing its surface area to increase nutrient absorption. The intestine has its own pair of muscle layers like the body, but in reverse order: an inner circular layer within an outer longitudinal layer.
Corruption in Iran's water supply sector has deep roots and manifests through misallocation of resources, illegal water extraction, lack of transparency, and neglect of marginalized communities. Iran's water management system has been plagued by political favoritism. The IRGC and other politically connected entities control water resources, prioritizing projects for political and economic gain rather than public need. They divert supplies to favored regions, causing shortages in vulnerable provinces like Khuzestan and Sistan-Baluchestan. For example, water diversion projects in Isfahan and Yazd provinces received priority despite critical shortages in Khuzestan and Sistan-Baluchestan. Reports also indicate that certain agricultural and industrial enterprises with ties to the Iranian Revolutionary Guard Corps (IRGC) have received significant amounts of water, while small farmers and rural communities struggle with severe shortages. In addition, rural and minority populations face ecological degradation and a loss of livelihoods. This pattern of unequal development not only exacerbates regional disparities but also fuels social unrest. Iran's water policy is also characterized by an overreliance on dam construction and large-scale diversion projects, primarily benefiting politically connected enterprises and urban elites. The IRGC, through its construction arm Khatam al-Anbiya, monopolizes Iran's water management.
During the 2024 Syrian opposition offensives that toppled the Assad regime in Syria, Trump said that the U.S. should stay out of the conflict. In March 2025, Rubio condemned the massacres of Syrian Alawites. Trump agreed to lift sanctions on Syria after discussing the situation with Mohammed bin Salman and Erdoğan in May 2025.
Sources: en.wikipedia.org
Dehydrogenases oxidize a substrate by transferring hydrogen to an electron acceptor, common electron acceptors being NAD+ or FAD. This would be considered an oxidation of the substrate, in which the substrate either loses hydrogen atoms or gains an oxygen atom (from water). The name "dehydrogenase" is based on the idea that it facilitates the removal (de-) of hydrogen (-hydrogen-) and is an enzyme (-ase). Dehydrogenase reactions come most commonly in two forms: the transfer of a hydride and release of a proton (often with water as a second reactant), and the transfer of two hydrogens.
== Early life == Hofmeister's father was a doctor in Prague, where Hofmeister first began his studies, under the physiologist Karl Hugo Huppert, himself a student of Carl Lehmann. Hofmeister's Habilitationsschrift in 1879 concerned the peptic products of digestion. Hofmeister became a Professor of Pharmacology at the First Faculty of Medicine, Charles University in Prague in 1885, then eventually moved to Strasbourg in 1896.
=== Induced resistance === Induced resistance is another mechanism that algae develop to defend against algicidal bacteria. One example, Chaetoceros didymus, was found to be resistant to the algicidal bacterium Kordia algicida by producing its own proteases. These proteases are believed to counteract the lytic enzymes produced by the bacteria. Such a resistance response can be triggered not only by direct contact with bacteria but also by chemical signals present in bacterial culture filtrates.
16 November – The SNP's National Executive Committee proposes cutting the number of staff at its headquarters from 26 to 16. Ruth Maguire, MSP for Cunninghame South, announces she will not seek re-election at the 2026 Scottish Parliament election because she is to undergo treatment for cancer. 17 November – At 12pm, Tesco opens its branch in Stornaway, Isle of Lewis for the first time on a Sunday, the Western Isles being the only place in the UK where the majority of shops remain closed on a Sunday. 19 November – Scottish Labour leader Anas Sarwar says his party will expand the eligibility for winter fuel payments in Scotland if they win the 2026 Scottish Parliament election. Eric Trump, the son of Donald Trump, confirms the US President-elect will visit Scotland in 2025 to open a new golf course. The Scottish Government is reported to be preparing to reduce the minimum term served by prisoners given short sentences, which could lead to the early release of between 260 and 390 prisoners in February 2025. 20 November – The Children and Young People's Commissioner Scotland launches an investigation into Police Scotland's use of force against children. 21 November – Stephen Flynn, the SNP's leader at Westminster, says he will not seek a dual mandate by standing for the Scottish Parliament while he remains an MP. Traditional Scottish singer Iona Fyfe is named as the new Rector of the University of Aberdeen, succeeding Martina Chukwuma–Ezike, and will take up the post on 1 January 2025.
=== Pharmacodynamics === Methylephedrine is a sympathomimetic and ephedrine-like agent. Ephedrine and related agents act as norepinephrine releasing agents and hence as indirectly acting sympathomimetics. In relation to this, methylephedrine stimulates α- and β-adrenergic receptors. The drug has bronchodilator and nasal decongestant effects. The occupancy of the dopamine transporter (DAT) by racemic methylephedrine has been studied.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.